(PubMed) Strickland KC, Hoeferlin LA, Oleinik NV, Krupenko NI, Krupenko SA
10: Kroetz T , Dos Santos MC , Beal R , Zanotto GM , Santos FS , Giacomelli FC , Gonalves PFB , de Lima VR , Dal-B AG , Rodembusch FS
Unlike native IGF-1, which requires frequent administration due to its short half-life and extensive IGFBP binding, IGF-1 LR3's enhanced stability and bioavailability make it a more practical candidate for investigating growth factor-mediated tissue regeneration and metabolic regulation
Cao, P., et al., Therapeutic approaches to modulating glutathione levels as a pharmacological strategy in Alzheimers disease
We help you choose the right option during your visit